Dechra Pharmaceutical shares a ‘long-term value hold’
September 7, 2015 3:04 pm
7 September 2015: Dechra Pharmaceuticals CEO Ian Page says they will continue to see continued growth in the US, a steady increase in presence in the rest of the world and their product portfolio will continue to deliver results. He says they are looking to maintain double-digit underlying earnings growth in FY16. In regards to the share price, he feels it got overheated but has found its natural level, and if they keep delivering growth the share price will look after itself.
7 September 2015: Dechra Pharmaceuticals CEO Ian Page says they will continue to see continued growth in the US, a steady increase in presence in the rest of the world and their product portfolio will continue to deliver results. He says they are looking to maintain double-digit underlying earnings growth in FY16. In regards to the share price, he feels it got overheated but has found its natural level, and if they keep delivering growth the share price will look after itself.
Related Posts: